ClinicalTrials.gg
Not yet recruitingNCT07679789CHLAMPACUpdated Jul 1, 2026

Community-acquired Pneumonia Due to Chlamydia Pneumoniae

An observational study in Community-Acquired Pneumonia, sponsored by Centre Hospitalier de Saint-Denis. Not yet recruiting at 1 site in France. Per ClinicalTrials.gov, last updated 2026-07-01.

Sponsored by Centre Hospitalier de Saint-Denis · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Retrospective
Enrollment
200
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 40 studies in Community-Acquired Pneumonia with a site in France — 11 open to participants now, 11 under way, 5 of them phase 3. Community-Acquired Pneumonia · France.

Planned enrollment
10th of 14
200 · median 365
Started
2026
with 1 other
Observational
14 of 40
2 open now
Primary completion
2026-09
later than 1 of 10 live
Registered
40th of 40
by date
Lead sponsor
1 of 40
Centre Hospitalier de Saint-Denis

Among the 40 studies in Community-Acquired Pneumonia with a site in France, this one is the 10th largest by planned enrollment of the 14 observational ones that give a count, is one of 2 that started in 2026, is one of 14 observational ones, reaches primary completion later than 1 of the 10 other live ones, and was the 40th registered.

Community-Acquired Pneumonia

325 studies on the registry are indexed under Community-Acquired Pneumonia; 77 are open to participants now.

Browse Community-Acquired Pneumonia studies →

Open to participants now

11 of the 40 studies in Community-Acquired Pneumonia with a site in France are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 41 Community-Acquired Pneumonia studies recruiting now, 29 (71%) set no upper age limit and 9 (22%) stop at 75 or younger; 13 take children under 18; 5 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Community-Acquired Pneumonia with a site in France, or all of them as a file.
02

Study summary

This international retrospective Franco-Swiss study focuses on community-acquired pneumonia (CAP) caused by Chlamydia pneumoniae.

The working hypothesis is that the prevalence of C. pneumoniae pneumonia is overestimated by the medical community.

The primary objective is to determine the true prevalence of C. pneumoniae infections among patients with pneumonia who underwent simplex or multiplex PCR testing.

Secondary objectives include;

  1. Outpatient management
  2. Hospitalization in a medical ward
  3. Admission to the intensive care unit
  4. In-hospital mortality
  5. Radiological presentation of patients with community-acquired pneumonia (CAP) caused by Chlamydia pneumoniae
  6. Prevalence of viral or bacterial co-infections associated with C. pneumoniae CAP
Read the detailed description

This international retrospective Franco-Swiss study focuses on community-acquired pneumonia (CAP) caused by Chlamydia pneumoniae. The working hypothesis is that the prevalence of C. pneumoniae pneumonia is overestimated by the medical community. The primary objective is to determine the true prevalence of C. pneumoniae infections among patients with pneumonia who underwent simplex or multiplex PCR testing. Secondary objectives include;1)Outpatient management2)Hospitalization in a medical ward3)Admission to the intensive care unit4) In-hospital mortality5) Radiological presentation of patients with community-acquired pneumonia (CAP) caused by Chlamydia pneumoniae 6)Prevalence of viral or bacterial co-infections associated with C. pneumoniae CAP

Detailed Description We have all learned and continue to teach that community-acquired pneumonia (CAP) is essentially represented by three bacteria: Legionella pneumophila, Mycoplasma pneumoniae, and Chlamydia pneumoniae. While the recent Mycoplasma outbreak in France and the prevalence of severe Legionella infections in intensive care units confirm the real impact of these pathogens in CAP, the low number of Chlamydia pneumoniae cases documented by PCR raises questions.Over the past twenty years, the development of highly sensitive molecular tests (specific PCR or multiplex PCR targeting intracellular respiratory pathogens) has made it possible to precisely detect Chlamydia pneumoniae and to confirm or rule out its presence in the respiratory tract of patients with pneumonia.We are therefore conducting a retrospective study between France and Switzerland to determine, on the one hand, the number of CAP cases due to Chlamydia pneumoniae confirmed by PCR, and on the other hand, to better characterize the phenotype of these patients.

03

Conditions studied

  • Community-Acquired Pneumonia

Keywords

  • Chlamydia pneumoniae
  • Community-acquired pneumonia
  • Prevalence
  • PCR
  • Co-infection
  • Respiratory infection
  • Atypical pneumonia
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population consists of pediatric and adult patients from participating French and Swiss centers who had a positive simplex or multiplex PCR result for Chlamydia pneumoniae on an upper or lower respiratory tract specimen between January 2015 and December 2025. Eligible patients must have a documented diagnosis of pneumonia and available clinical data allowing characterization of disease presentation, management, radiological findings, co-infections, and outcomes. Patients who objected to the use of their medical data for research purposes or who did not have pneumonia are excluded.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Positive simplex or multiplex PCR for Chlamydia pneumoniae on an upper or lower respiratory tract specimen between January 2015 and December 2025.
  • Availability of clinical data allowing confirmation of pneumonia diagnosis.

Exclusion criteria

Exclusion Criteria:

  • Patient opposition to the use of medical data for research purposes.
  • Absence of pneumonia diagnosis.
  • Insufficient clinical data for analysis.
05

Study design

Observational model
Other
Time perspective
Retrospective
Enrollment
200 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Prevalence of Chlamydia pneumoniae Among Pneumonia Cases Tested by PCR

    Proportion of pneumonia cases with a positive simplex or multiplex PCR for Chlamydia pneumoniae among all patients who underwent respiratory PCR testing during the study period.

    Time frame: January 2015 to December 2025

Secondary outcomes

  1. Clinical Severity of Chlamydia pneumoniae Pneumonia

    Distribution of patients according to outpatient management, hospitalization in a medical ward, admission to intensive care, and in-hospital mortality.

    Time frame: From hospital admission through hospital discharge (up to 90 days)

  2. Radiological Characteristics

    Chest radiograph and chest computed tomography findings associated with PCR-confirmed Chlamydia pneumoniae pneumonia.

    Time frame: Baseline (at the time of pneumonia diagnosis)

  3. Viral Co-Infection Rate

    Proportion of patients with concomitant viral infection identified by microbiological testing.

    Time frame: Baseline (at the time of PCR testing)

  4. Bacterial Co-Infection Rate

    Proportion of patients with concomitant bacterial infection identified by microbiological testing.

    Time frame: Baseline (at the time of PCR testing)

  5. Length of Hospital Stay

    Duration of hospitalization among admitted patients.

    Time frame: From hospital admission through hospital discharge (up to 90 days)

07

Study locations

1 site
08

References and documents

Publications

  • Garin N, Hugli O, Genne D, Greub G. Lack of Chlamydia-related bacteria among patients with community-acquired pneumonia. New Microbes New Infect. 2015 Oct 22;8:164-5. doi: 10.1016/j.nmni.2015.10.002. eCollection 2015 Nov. No abstract available. PubMed 27257497 ↗
  • Garin N, Marti C, Skali Lami A, Prendki V. Atypical Pathogens in Adult Community-Acquired Pneumonia and Implications for Empiric Antibiotic Treatment: A Narrative Review. Microorganisms. 2022 Nov 24;10(12):2326. doi: 10.3390/microorganisms10122326. PubMed 36557579 ↗
  • Miyashita N. Atypical pneumonia: Pathophysiology, diagnosis, and treatment. Respir Investig. 2022 Jan;60(1):56-67. doi: 10.1016/j.resinv.2021.09.009. Epub 2021 Nov 5. PubMed 34750083 ↗
  • Cunha BA. The atypical pneumonias: clinical diagnosis and importance. Clin Microbiol Infect. 2006 May;12 Suppl 3:12-24. doi: 10.1111/j.1469-0691.2006.01393.x. PubMed 16669925 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jun 2026; primary completion for Sep 2026, 3 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2026
First posted
Jul 1, 2026
StartEst.
Jun 2026
Primary completionEst.
Sep 2026
CompletionEst.
Jun 2027
Last update
Jul 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07679789
Lead sponsor
Centre Hospitalier de Saint-Denis
Responsible party
Sponsor
First posted
Jul 1, 2026
Start date
Jun 2026 (estimated)
Primary completion
Sep 2026 (estimated)
Completion
Jun 2027 (estimated)
Last update
Jul 1, 2026

Study contacts

Yacine Tandjaoui-Lambiotte, Principal Investigator
Contact
yacine.tandjaouilambiotte@ch-stdenis.fr
+33 1 42 35 61
Clinical Research Unit Coordinator Clinical Research Unit Coordinator, GHT Plaine de France Clinical
Contact
coordination.rechercheclinique@ghtpdfr.fr
+33 1 42 35 61 40 ext. 6962

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion